2025
Hypertension after solid-organ transplantation: special considerations for management
Feliberti J, Alam A, Maulion C. Hypertension after solid-organ transplantation: special considerations for management. Current Opinion In Cardiology 2025, 40: 193-198. PMID: 40401425, DOI: 10.1097/hco.0000000000001230.Peer-Reviewed Original ResearchConceptsBaroreflex activation therapySolid organ transplantationHeart transplantationRenal denervationGLP-1R agonistsGLP-1RActive therapyMedical managementMedical management of hypertensionTherapy of heart failureReinitiation of therapyAngiotensin-converting enzyme inhibitorsCalcium channel blockersAngiotensin receptor blockersCardiovascular outcome trialsGlucagon-like peptide-1 receptorOptimal medical managementIncidence of hypertensionManagement of hypertensionImmunosuppressive therapyRefractory hypertensionPeptide-1 receptorChannel blockersRenal transplantationReceptor blockers
2024
899-P: Combinations of the Mitochondrial Protonophore TLC-6740 and/or the ACC2 Inhibitor TLC-3595 Provide Additive Glycemic Benefits to Semaglutide (SEMA) in db/db Mice
VIJAYAKUMAR A, SRODA N, MURAKAMI E, WENG S, MYERS R, SUBRAMANIAN M, SHULMAN G. 899-P: Combinations of the Mitochondrial Protonophore TLC-6740 and/or the ACC2 Inhibitor TLC-3595 Provide Additive Glycemic Benefits to Semaglutide (SEMA) in db/db Mice. Diabetes 2024, 73 DOI: 10.2337/db24-899-p.Peer-Reviewed Original ResearchOral glucose tolerance testGLP-1R agonistsDb/db miceIncremental AUCGlucose tolerance testMale db/db miceImproved glucose toleranceSemaglutide groupGlycemic parametersSemaglutideTolerance testFood intakeGlucose toleranceGLP-1RLiver-targeted mitochondrial uncouplerDb/dbMiceGlucose bolusVEHAgonistsEvaluation of combinationsHbA1cDiabetesMitochondrial uncouplingAssess effects
2018
Liraglutide Modulates Appetite and Body Weight Via GLP-1R-Expressing Glutamatergic Neurons
Adams J, Pei H, Sandoval D, Seeley R, Chang R, Liberles S, Olson D. Liraglutide Modulates Appetite and Body Weight Via GLP-1R-Expressing Glutamatergic Neurons. Diabetes 2018, 67: db171385. PMID: 29776968, PMCID: PMC6054439, DOI: 10.2337/db17-1385.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAppetite DepressantsDiet, High-FatEnergy IntakeGABAergic NeuronsGenes, ReporterGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsGreen Fluorescent ProteinsHypoglycemic AgentsHypothalamusLiraglutideMaleMice, KnockoutMice, TransgenicNerve NetNerve Tissue ProteinsNeuronsObesityRandom AllocationRecombinant Fusion ProteinsVesicular Glutamate Transport Protein 2Vesicular Inhibitory Amino Acid Transport ProteinsWeight LossConceptsGlutamatergic neuronsGLP-1RsGABAergic neuronsGLP-1RVisceral illnessLiraglutide-induced weight lossNeural network activityGLP-1R expressionGlucagon-like peptide 1 receptorWeight loss drugsBody weightGLP-1R agonistsPeptide 1 receptorSite of actionNetwork activityFood intakeLiraglutide administrationLiraglutideLong-term effectsNeuronsWeight lossAgonistsPhysiological effectsIllnessDeletion
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply